Acceptability Research on Integrated Point of Care Sexually Transmitted Infection (STI) Testing a… (NCT06570733) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Acceptability Research on Integrated Point of Care Sexually Transmitted Infection (STI) Testing and Expedited Partner Therapy (EPT)
South Africa305 participantsStarted 2022-02-11
Plain-language summary
This protocol builds on nearly a decade of collaborative HIV/STI prevention research to conduct a prospective cohort study of Adolescent Girls and Young Women (AGYW) eligible for PrEP in South Africa in which we will assess the acceptability of point-of-care STI testing plus Expedited Partner Therapy (EPT) and its impact on the incidence of common curable STIs over 12 months of follow-up. The social-behavioral scientist will undertake qualitative interviews with participants and their male partners to identify facilitators and barriers to EPT uptake and conduct a comparative cost analysis to estimate the cost per person tested using point-of-care STI testing with and without EPT incremental to the cost of standard of care. Findings from the proposed research will provide essential knowledge for national policymakers to advance approaches to STI screening and treatment that will lead to improvements in AGYW sexual reproductive health and reductions in STIs. The data generated from this project are essential to inform efforts to reduce the burden of STIs and HIV-1 in women and achieve the 2030 Sustainable Development Goals, which includes substantial reductions in HIIV and STIs in key at-risk populations. This project will support global efforts to substantially reduce STIs in key populations.
Who can participate
Age range16 Years – 25 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Cisgender girls and women (16-25 years of age, inclusive)
✓. Vaginal sex with a cisgender male partner in the last three months
✓. CT, GC, or TV detected at screening
✓. Willing to return for quarterly study visits
✓. Not currently pregnant and not planning to become pregnant in the next 12 months
✓. Using or willing to initiate a highly effective method of contraception\*
✓. HIV-uninfected
✓. Interested in initiating oral PrEP
Exclusion criteria
✕. At Screening or Enrollment, participant reports known adverse reaction to FTC or TDF.
✕. At Screening or Enrollment, has single or dual rapid Antibody positive reactive HIV-1 test.
What they're measuring
1
GeneXpert
Timeframe: 2 years
Trial details
NCT IDNCT06570733
SponsorWits RHI Research Centre Clinical Research Site
. At Screening or Enrollment, is already participating in another research study involving drugs, medical devices, or vaccines for STI prevention or treatment.
✕. As determined by the PIs/designee, any current or historical physical health, mental health or social issue or condition that the site investigator or designee determines should exclude participation.
✕. Has any other condition that, in the opinion of the PIs/designee, would preclude informed consent, make study participation unsafe, or otherwise interfere with achieving the study objectives.